BPC-157 and Ipamorelin

Mentioned together

Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.

How the two mechanisms relate

Neutral. BPC-157, studied in tissue-injury models, and Ipamorelin, a ghrelin-receptor agonist, are named together in research reviews but act on unrelated pathways, with no combined data recorded here.

This reading describes mechanism and is editorial. The grade above is the published record.

The compounds

BPC-157

A pentadecapeptide studied mostly in animal models of tissue injury. Human evidence is small and uncontrolled, and no regulator has approved it.

Full profile, dosing and safety →

Ipamorelin

A selective growth-hormone secretagogue and ghrelin-receptor agonist. Outcome data are animal, and two completed human trials report status and title only.

Full profile, dosing and safety →

Check these in the interaction tool →